Results 81 to 90 of about 34,135 (204)

Combinations of PARP Inhibitors with Temozolomide Drive PARP1 Trapping and Apoptosis in Ewing's Sarcoma. [PDF]

, 2015
Ewing's sarcoma is a malignant pediatric bone tumor with a poor prognosis for patients with metastatic or recurrent disease. Ewing's sarcoma cells are acutely hypersensitive to poly (ADP-ribose) polymerase (PARP) inhibition and this is being evaluated in
Barthorpe, Syd, Benes, Cyril H, Garnett, Mathew J, Gill, Sonja J, Jackson, Stephen P, Kogera, Fiona A, McDermott, Ultan, Mironenko, Tatiana, Pshenichnaya, Irina, Richardson, Laura, Stratton, Michael R, Travers, Jon   +11 more
core   +5 more sources

Clinical trial of safety and antitumor activity of farletuzumab ecteribulin in patients with platinum‐resistant ovarian cancer: Phase I expansion results

International Journal of Gynecology &Obstetrics, EarlyView.
Abstract Objective In the dose‐escalation part of Study 101, which included multiple tumor types, objective responses were observed in 10 of 22 patients across multiple dose levels of farletuzumab ecteribulin (FZEC). We explored the safety/antitumor activity of FZEC in patients with platinum‐resistant ovarian cancer (PROC) from the Study 101 expansion ...
Kan Yonemori, Mayu Yunokawa, Koji Matsumoto, Kazuhiro Takehara, Kosei Hasegawa, Yasuyuki Hirashima, Hidenori Kato, Hiroki Ikezawa, Yohei Otake, Wataru Yusa, Takuma Miura, Shin Nishio   +11 more
wiley   +1 more source

The efficacy and safety of PARP inhibitors in mCRPC with HRR mutation in second-line treatment: a systematic review and bayesian network meta-analysis

BMC Cancer
Background Poly (ADP- ribose) polymerase inhibitors (PARPi) has been increasingly adopted for metastatic castration-resistance prostate cancer (mCRPC) patients with homologous recombination repair deficiency (HRD).
Qiyu Zhu, Junru Chen, Haoyang Liu, Jinge Zhao, Chenhao Xu, Guangxi Sun, Hao Zeng   +6 more
doaj   +1 more source

Phosphorylation of ribosomal protein S6 confers PARP inhibitor resistance in BRCA1-deficient cancers [PDF]

, 2014
Inhibition of poly(ADP-ribose) polymerase (PARP) is a promising therapeutic strategy for BRCA1 deficient cancers, however, the development of drug resistance limits clinical efficacy.
Chen, Qianming, Hu, Mickey C T, Huang, Yuping, Pandita, Tej K, Sun, Chong-kui, Xiang, Tao, Yang, Qin, Zhang, Fan   +7 more
core   +3 more sources

Ovarian Cancer: Epidemiology, Disease Mechanisms, New Diagnosis and Treatment Strategies, and Research Directions

iNew Medicine, EarlyView.
ABSTRACT Ovarian cancer (OC) continues to be the deadliest gynecological malignancy and a significant cause of cancer‐related mortality among women worldwide. Standard treatment strategies typically entail platinum‐based chemotherapy in conjunction with cytoreductive surgery.
Zunera Khalid, Weirong Fan, Farah Nazir, Yixiang Xing, Tengchuan Jin   +4 more
wiley   +1 more source

BMN673 sensitizes rhabdomyosarcoma tumors to irradiation in vivo [PDF]

, 2020
Bone and soft tissue sarcomas are mesenchymal tumors that occur rarely in adults, representing only 1% of total malignancies, but comprise up to 13% of malignant tumors in children.1 Rhabdomyosarcoma, a soft tissue sarcoma that commonly affects children,
Jacob, Connor
core  

Deubiquitinase USP38 Stabilizes PLK1 Expression to Boost DNA Damage Repair in Ovarian Cancer

The Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT Ovarian cancer (OC) is one of the most prevalent and severe gynecological malignant tumors. DNA damage repair (DDR) is essential in maintaining genome stability. This study aims to investigate the effects and mechanisms of USP38 and PLK1 on DNA damage repair and malignant behavior in OC cells.
Yuan Ma, Ying Li, Kai‐Li Li
wiley   +1 more source

The poly (ADP-ribose) polymerase inhibitor olaparib attenuates established pulmonary fibrosis in a large animal model

BMC Pulmonary Medicine
Background Poly (ADP‒ribose) polymerase (PARP) is a constitutive enzyme involved in regulating various biological processes in health and disease. In the present study, we investigated the role of PARP1 in pulmonary fibrosis and assessed the efficacy of ...
Habtamu B. Derseh, Andrew N. Davies, Alarna Young, Sylvie Bischof, Joseph Pelle, David Rudd, Michelle McIntosh, David Piedrafita, Robert J. Bischof   +8 more
doaj   +1 more source

Next-generation sequencing of prostate cancer: genomic and pathway alterations, potential actionability patterns, and relative rate of use of clinical-grade testing. [PDF]

, 2019
Despite being one of the most common cancers, treatment options for prostate cancer are limited. Novel approaches for advanced disease are needed. We evaluated the relative rate of use of clinical-grade next generation sequencing (NGS) in prostate cancer,
Carter, Jennifer L, Elkin, Sheryl K, Ikeda, Sadakatsu, Kurzrock, Razelle, Tomson, Brett N   +4 more
core  

Sublethal concentrations of 17-AAG suppress homologous recombination DNA repair and enhance sensitivity to carboplatin and olaparib in HR proficient ovarian cancer cells [PDF]

, 2014
The promise of PARP-inhibitors(PARPis) in the management of epithelial ovarian cancer(EOC) is tempered by the fact that approximately 50% of patients with homologous recombination (HR)-proficient tumors do not respond well to these agents. Combination of
Battelli, Chiara, Choi, Young Eun, Chowdhury, Dipanjan, Curtis, Jennifer, Konstantinopoulos, Panagiotis A., Liu, Joyce, Matulonis, Ursula A., Morse, Alexander N., Watson, Jacqueline   +8 more
core   +1 more source